Výsledky vyhledávání - "Danny H. Sugimoto"

Author response for 'IDegLira improves patient reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal–bolus therapy'

Autor: Liana K. Billings, Danny H. Sugimoto, Randi Grøn, Ankur Doshi, Nikolaos Tentolouris, Esteban Jódar, Adie Viljoen, Eden Miller, Mattis F. Ranthe, Petra Őrsy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b1f503a274322a371cbc973978c1e99
https://doi.org/10.1111/dom.13851/v2/response1

Zobrazit plný text záznamu

IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy

Autor: Mattis F. Ranthe, Petra Őrsy, Danny H. Sugimoto, Randi Grøn, Eden Miller, Ankur Doshi, Adie Viljoen, Nikolaos Tentolouris, Esteban Jódar, Liana K. Billings

Publikováno v: ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Diabetes, Obesity & Metabolism

Aims: Basal-bolus therapy is associated with greater treatment burden and lower adherence compared with more simplified regimens. This post hoc analysis studied the difference between insulin degludec/liraglutide (IDegLira) and basal-bolus therapy on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d4ec479bf87e61619f5905d5e9868a9
http://hdl.handle.net/11268/10211

Zobrazit plný text záznamu

Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as at high or low risk according to HEDIS measurements

Autor: Vanita R. Aroda, Danny H. Sugimoto, Terry Dex, William Stager

Publikováno v: Diabetes, obesitymetabolism. 20(11)

The Healthcare Effectiveness Data and Information Set (HEDIS) measurements assess glycaemic goal attainment in patients with type 2 diabetes, incorporating factors including age and health status. Healthier patients are assigned a glycated haemoglobi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5d43e953fdd55b3f6b7594fbecb4676
https://pubmed.ncbi.nlm.nih.gov/29923361

Zobrazit plný text záznamu

A placebo-controlled, dose-response study of dexfenfluramine in the treatment of obese patients

Autor: Thomas C. Marbury, Danny H. Sugimoto, R. Michael Gulley, Arthur Krosnick, John E. Angelo, Stephen R. Zellner

Publikováno v: Current Therapeutic Research. 57:663-674

A randomized, placebo-controlled, multicenter, parallel-group study was performed to determine which of three dose levels of dexfenfluramine (Dfen)—10, 30, or 60 mg/d—in combination with a sex- and body weight—specific reduction in caloric inta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5d7b1d5929edea3faa48ff9f4a4597f4
https://doi.org/10.1016/s0011-393x(96)80071-3

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání